Pöhlmann, Stefan

[["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Journal of Virology"],["dc.bibliographiccitation.volume","93"],["dc.contributor.author","Hoffmann, Markus"],["dc.contributor.author","Nehlmeier, Inga"],["dc.contributor.author","Brinkmann, Constantin"],["dc.contributor.author","Krähling, Verena"],["dc.contributor.author","Behner, Laura"],["dc.contributor.author","Moldenhauer, Anna-Sophie"],["dc.contributor.author","Krüger, Nadine"],["dc.contributor.author","Nehls, Julia"],["dc.contributor.author","Schindler, Michael"],["dc.contributor.author","Hoenen, Thomas"],["dc.contributor.author","Maisner, Andrea"],["dc.contributor.author","Becker, Stephan"],["dc.contributor.author","Pöhlmann, Stefan"],["dc.contributor.editor","Dermody, Terence S."],["dc.date.accessioned","2020-12-10T18:37:03Z"],["dc.date.available","2020-12-10T18:37:03Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1128/JVI.01821-18"],["dc.identifier.eissn","1098-5514"],["dc.identifier.issn","0022-538X"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/76825"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Tetherin Inhibits Nipah Virus but Not Ebola Virus Replication in Fruit Bat Cells"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e00403-18"],["dc.bibliographiccitation.issue","13"],["dc.bibliographiccitation.journal","Journal of Virology"],["dc.bibliographiccitation.volume","92"],["dc.contributor.author","González-Hernández, Mariana"],["dc.contributor.author","Hoffmann, Markus"],["dc.contributor.author","Brinkmann, Constantin"],["dc.contributor.author","Nehls, Julia"],["dc.contributor.author","Winkler, Michael"],["dc.contributor.author","Schindler, Michael"],["dc.contributor.author","Pöhlmann, Stefan"],["dc.contributor.editor","Dermody, Terence S."],["dc.date.accessioned","2022-10-06T13:25:33Z"],["dc.date.available","2022-10-06T13:25:33Z"],["dc.date.issued","2018"],["dc.description.abstract","ABSTRACT\n The interferon-induced antiviral host cell protein tetherin can inhibit the release of several enveloped viruses from infected cells. The Ebola virus (EBOV) glycoprotein (GP) antagonizes tetherin, but the domains and amino acids in GP that are required for tetherin antagonism have not been fully defined. A GXXXA motif within the transmembrane domain (TMD) of EBOV-GP was previously shown to be important for GP-mediated cellular detachment. Here, we investigated whether this motif also contributes to tetherin antagonism. Mutation of the GXXXA motif did not impact GP expression or particle incorporation and only modestly reduced EBOV-GP-driven entry. In contrast, the GXXXA motif was required for tetherin antagonism in transfected cells. Moreover, alteration of the GXXXA motif increased tetherin sensitivity of a replication-competent vesicular stomatitis virus (VSV) chimera encoding EBOV-GP. Although these results await confirmation with authentic EBOV, they indicate that a GXXXA motif in the TMD of EBOV-GP is important for tetherin antagonism. Moreover, they provide the first evidence that GP can antagonize tetherin in the context of an infectious EBOV surrogate.\n \n IMPORTANCE\n The glycoprotein (GP) of Ebola virus (EBOV) inhibits the antiviral host cell protein tetherin and may promote viral spread in tetherin-positive cells. However, tetherin antagonism by GP has so far been demonstrated only with virus-like particles, and it is unknown whether GP can block tetherin in infected cells. Moreover, a mutation in GP that selectively abrogates tetherin antagonism is unknown. Here, we show that a GXXXA motif in the transmembrane domain of EBOV-GP, which was previously reported to be required for GP-mediated cell rounding, is also important for tetherin counteraction. Moreover, analysis of this mutation in the context of vesicular stomatitis virus chimeras encoding EBOV-GP revealed that GP-mediated tetherin counteraction is operative in infected cells. To our knowledge, these findings demonstrate for the first time that GP can antagonize tetherin in infected cells and provide a tool to study the impact of GP-dependent tetherin counteraction on EBOV spread."],["dc.description.sponsorship"," Deutsche Forschungsgemeinschaft https://doi.org/10.13039/501100001659"],["dc.description.sponsorship"," Deutsche Forschungsgemeinschaft https://doi.org/10.13039/501100001659"],["dc.description.sponsorship"," Deutscher Akademischer Austauschdienst https://doi.org/10.13039/501100001655"],["dc.identifier.doi","10.1128/JVI.00403-18"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/114864"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-602"],["dc.relation.eissn","1098-5514"],["dc.relation.issn","0022-538X"],["dc.relation.orgunit","Deutsches Primatenzentrum"],["dc.rights.uri","https://journals.asm.org/non-commercial-tdm-license"],["dc.title","A GXXXA Motif in the Transmembrane Domain of the Ebola Virus Glycoprotein Is Required for Tetherin Antagonism"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","11075"],["dc.bibliographiccitation.issue","24"],["dc.bibliographiccitation.journal","Journal of Virology"],["dc.bibliographiccitation.lastpage","11086"],["dc.bibliographiccitation.volume","90"],["dc.contributor.author","Brinkmann, Constantin"],["dc.contributor.author","Nehlmeier, Inga"],["dc.contributor.author","Walendy-Gnirß, Kerstin"],["dc.contributor.author","Nehls, Julia"],["dc.contributor.author","González Hernández, Mariana"],["dc.contributor.author","Hoffmann, Markus"],["dc.contributor.author","Qiu, Xiangguo"],["dc.contributor.author","Takada, Ayato"],["dc.contributor.author","Schindler, Michael"],["dc.contributor.author","Pöhlmann, Stefan"],["dc.contributor.editor","Dermody, T. S."],["dc.date.accessioned","2022-10-06T13:25:36Z"],["dc.date.available","2022-10-06T13:25:36Z"],["dc.date.issued","2016"],["dc.description.abstract","ABSTRACT\n \n The glycoprotein of Ebola virus (EBOV GP), a member of the family\n Filoviridae\n , facilitates viral entry into target cells. In addition, EBOV GP antagonizes the antiviral activity of the host cell protein tetherin, which may otherwise restrict EBOV release from infected cells. However, it is unclear how EBOV GP antagonizes tetherin, and it is unknown whether the GP of Lloviu virus (LLOV), a filovirus found in dead bats in Northern Spain, also counteracts tetherin. Here, we show that LLOV GP antagonizes tetherin, indicating that tetherin may not impede LLOV spread in human cells. Moreover, we demonstrate that appropriate processing of N-glycans in tetherin/GP-coexpressing cells is required for tetherin counteraction by EBOV GP. Furthermore, we show that an intact receptor-binding domain (RBD) in the GP1 subunit of EBOV GP is a prerequisite for tetherin counteraction. In contrast, blockade of Niemann-Pick disease type C1 (NPC1), a cellular binding partner of the RBD, did not interfere with tetherin antagonism. Finally, we provide evidence that an antibody directed against GP1, which protects mice from a lethal EBOV challenge, may block GP-dependent tetherin antagonism. Our data, in conjunction with previous reports, indicate that tetherin antagonism is conserved among the GPs of all known filoviruses and demonstrate that the GP1 subunit of EBOV GP plays a central role in tetherin antagonism.\n \n \n IMPORTANCE\n Filoviruses are reemerging pathogens that constitute a public health threat. Understanding how Ebola virus (EBOV), a highly pathogenic filovirus responsible for the 2013-2016 Ebola virus disease epidemic in western Africa, counteracts antiviral effectors of the innate immune system might help to define novel targets for antiviral intervention. Similarly, determining whether Lloviu virus (LLOV), a filovirus detected in bats in northern Spain, is inhibited by innate antiviral effectors in human cells might help to determine whether the virus constitutes a threat to humans. The present study shows that LLOV, like EBOV, counteracts the antiviral effector protein tetherin via its glycoprotein (GP), suggesting that tetherin does not pose a defense against LLOV spread in humans. Moreover, our work identifies the GP1 subunit of EBOV GP, in particular an intact receptor-binding domain, as critical for tetherin counteraction and provides evidence that antibodies directed against GP1 can interfere with tetherin counteraction."],["dc.identifier.doi","10.1128/JVI.01563-16"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/114875"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-602"],["dc.relation.eissn","1098-5514"],["dc.relation.issn","0022-538X"],["dc.relation.orgunit","Deutsches Primatenzentrum"],["dc.rights.uri","https://journals.asm.org/non-commercial-tdm-license"],["dc.title","The Tetherin Antagonism of the Ebola Virus Glycoprotein Requires an Intact Receptor-Binding Domain and Can Be Blocked by GP1-Specific Antibodies"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dspace.entity.type","Publication"]]